carvedilol has been researched along with Recrudescence in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The CAPRICORN (Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction) trial established that the beta-blocker carvedilol reduces the risk of death in patients with left ventricular dysfunction post myocardial infarction, whether or not the infarct is complicated by clinical heart failure." | 8.82 | New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients. ( Sackner-Bernstein, JD, 2003) |
| "Telmisartan was significantly more effective than carvedilol in preventing recurrent AF episodes in hypertensive AF patients, despite a similar lowering of blood pressure." | 6.77 | A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. ( Carbotta, S; Cittadini, A; Di Michele, S; Galzerano, D; Gaudio, C; Lama, D; Paolisso, G; Tedesco, MA; Tuccillo, B, 2012) |
| "Carvedilol was found to be safe, and it significantly reduced cardiac events compared with placebo (18 on carvedilol and 31 on placebo, P < ." | 6.68 | Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. ( Basu, S; Bruckner, T; Lahiri, A; Raval, U; Senior, R; van der Does, R, 1997) |
| "The CAPRICORN (Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction) trial established that the beta-blocker carvedilol reduces the risk of death in patients with left ventricular dysfunction post myocardial infarction, whether or not the infarct is complicated by clinical heart failure." | 4.82 | New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients. ( Sackner-Bernstein, JD, 2003) |
| "Carvedilol is a vasodilating non-selective β-blocker with alpha-1 receptor and calcium channel antagonism." | 2.79 | Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. ( Dickson, S; Forrest, EH; Gaya, DR; Hayes, PC; Leithead, JA; MacBeth, K; Mills, PR; Smith, L; Stanley, AJ; Suzuki, H; Tripathi, D; Young, D, 2014) |
| "Telmisartan was significantly more effective than carvedilol in preventing recurrent AF episodes in hypertensive AF patients, despite a similar lowering of blood pressure." | 2.77 | A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. ( Carbotta, S; Cittadini, A; Di Michele, S; Galzerano, D; Gaudio, C; Lama, D; Paolisso, G; Tedesco, MA; Tuccillo, B, 2012) |
| "Carvedilol was found to be safe, and it significantly reduced cardiac events compared with placebo (18 on carvedilol and 31 on placebo, P < ." | 2.68 | Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. ( Basu, S; Bruckner, T; Lahiri, A; Raval, U; Senior, R; van der Does, R, 1997) |
| "Carvedilol was more efficacious than traditional NSBBs in decreasing the variceal rebleeding rate [odds ratio (OR): 0." | 2.61 | The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis. ( Chen, L; Ge, K; Yang, J; Yang, JL, 2019) |
| "Thus, optimal treatment of portal hypertension requires a strategy that takes into account the clinical stage of the disease and all the major variables that affect the risk of progression to the next stage and death." | 2.55 | Prevention and treatment of variceal haemorrhage in 2017. ( Berzigotti, A; Bosch, J; Brunner, F, 2017) |
| "Treatment of portal hypertension is evolving based on randomised controlled trials." | 2.42 | Management of portal hypertension. ( Burroughs, AK; Patch, DW; Samonakis, DN; Thalheimer, U; Triantos, CK, 2004) |
| "However, she experienced recurrence with positive T790 M, and osimertinib (80 mg/day) was administered as the 2nd line therapy." | 1.56 | Osimertinib induced cardiomyopathy: A case report. ( Ishikawa, K; Kagamu, H; Kaira, K; Shinomiya, S; Yamaguchi, O, 2020) |
| "Treatment with carvedilol restored VMH lactate levels and improved the adrenaline (epinephrine) responses." | 1.51 | Carvedilol prevents counterregulatory failure and impaired hypoglycaemia awareness in non-diabetic recurrently hypoglycaemic rats. ( Chan, O; Farhat, R; Fisher, SJ; Knight, N; Sejling, AS; Su, G, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, WC | 2 |
| Hou, MC | 2 |
| Shinomiya, S | 1 |
| Kaira, K | 1 |
| Yamaguchi, O | 1 |
| Ishikawa, K | 1 |
| Kagamu, H | 1 |
| Tanaka, S | 1 |
| Imamura, T | 1 |
| Ueno, H | 1 |
| Kinugawa, K | 1 |
| Farhat, R | 2 |
| de Santana-Van Vliet, E | 1 |
| Su, G | 2 |
| Neely, L | 1 |
| Benally, T | 1 |
| Chan, O | 2 |
| Zhang, JG | 1 |
| Dai, SP | 1 |
| Liu, H | 1 |
| Xu, ZS | 1 |
| Sejling, AS | 1 |
| Knight, N | 1 |
| Fisher, SJ | 1 |
| Hsin, IF | 1 |
| Chen, PH | 1 |
| Hsu, PI | 1 |
| Wang, YP | 1 |
| Cheng, JS | 1 |
| Lin, HS | 1 |
| Lee, FY | 1 |
| Yang, J | 1 |
| Ge, K | 1 |
| Chen, L | 1 |
| Yang, JL | 1 |
| Fonarow, G | 1 |
| Stanley, AJ | 1 |
| Dickson, S | 1 |
| Hayes, PC | 1 |
| Forrest, EH | 1 |
| Mills, PR | 1 |
| Tripathi, D | 1 |
| Leithead, JA | 1 |
| MacBeth, K | 1 |
| Smith, L | 1 |
| Gaya, DR | 1 |
| Suzuki, H | 1 |
| Young, D | 1 |
| Brunner, F | 1 |
| Berzigotti, A | 1 |
| Bosch, J | 1 |
| Shimada, YJ | 1 |
| Sato, K | 1 |
| Hanon, S | 1 |
| Schweitzer, P | 1 |
| Tsuda, E | 1 |
| Matsuo, M | 1 |
| Sakaguchi, H | 1 |
| Hayashi, T | 1 |
| Hosoda, K | 1 |
| Miyazaki, A | 1 |
| Galzerano, D | 1 |
| Di Michele, S | 1 |
| Paolisso, G | 1 |
| Tuccillo, B | 1 |
| Lama, D | 1 |
| Carbotta, S | 1 |
| Cittadini, A | 1 |
| Tedesco, MA | 1 |
| Gaudio, C | 1 |
| Otterstad, JE | 1 |
| Ford, I | 1 |
| Isnard, R | 1 |
| Sackner-Bernstein, JD | 1 |
| Samonakis, DN | 1 |
| Triantos, CK | 1 |
| Thalheimer, U | 1 |
| Patch, DW | 1 |
| Burroughs, AK | 1 |
| Okumura, Y | 1 |
| Watanabe, I | 1 |
| Nakai, T | 1 |
| Sugimura, H | 1 |
| Hashimoto, K | 1 |
| Masaki, R | 1 |
| Ohkubo, K | 1 |
| Takagi, Y | 1 |
| Shindo, A | 1 |
| Ozawa, Y | 1 |
| Saito, S | 1 |
| Kanmatsuse, K | 1 |
| Fonarow, GC | 1 |
| Lukas, MA | 1 |
| Robertson, M | 1 |
| Colucci, WS | 1 |
| Dargie, HJ | 1 |
| Zehender, M | 1 |
| Just, H | 1 |
| Wright, DJ | 1 |
| Cooke, GA | 1 |
| Tan, LB | 1 |
| Basu, S | 1 |
| Senior, R | 1 |
| Raval, U | 1 |
| van der Does, R | 1 |
| Bruckner, T | 1 |
| Lahiri, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding[NCT02504723] | Phase 4 | 121 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All adverse effects during the study period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 32 |
| Cyanoacrylate Injection | 9 |
All cause mortality or liver transplantation during the study period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 13 |
| Cyanoacrylate Injection | 20 |
All upper gastrointestinal bleeding during the follow-up period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 17 |
| Cyanoacrylate Injection | 29 |
Rebleeding from gastric varices during the follow-up period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 14 |
| Cyanoacrylate Injection | 21 |
6 reviews available for carvedilol and Recrudescence
| Article | Year |
|---|---|
The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Carvedilol; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices | 2019 |
Prevention and treatment of variceal haemorrhage in 2017.
Topics: Adrenergic beta-Antagonists; Anti-Bacterial Agents; Balloon Occlusion; Carbazoles; Carvedilol; Endos | 2017 |
[Congestive heart failure and acute myocardial infarction: latest trials with beta-blocking agents].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; | 2002 |
New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Therapy, Combination; Humans; Myocardial I | 2003 |
Management of portal hypertension.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Humans; Hyperte | 2004 |
[Value of beta-blocker therapy in treatment of coronary heart disease and sudden cardiac death with special reference to carvedilol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Coronary Disease; Death, Sudden | 1996 |
6 trials available for carvedilol and Recrudescence
| Article | Year |
|---|---|
Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Esophageal and Gastric V | 2014 |
A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Atrial Fibrillation; Benzimidazoles; Benzoates; Carbazoles; Ca | 2012 |
The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blo
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Double-Blind Me | 2002 |
Recurrence of atrial fibrillation after internal cardioversion of persistent atrial fibrillation: prognostic importance of electrophysiologic parameters.
Topics: Action Potentials; Aged; Atrial Fibrillation; Bepridil; Carbazoles; Carvedilol; Electric Countershoc | 2005 |
Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN).
Topics: Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Comorbidity; Double-Blind Method; Female; Hu | 2007 |
Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Dizziness; Echocard | 1997 |
11 other studies available for carvedilol and Recrudescence
| Article | Year |
|---|---|
Reply.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Re | 2019 |
Osimertinib induced cardiomyopathy: A case report.
Topics: Acrylamides; Adenocarcinoma of Lung; Adrenergic beta-Antagonists; Afatinib; Aged; Angiotensin-Conver | 2020 |
MitraClip or Ventricular Assist Device?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2020 |
Carvedilol prevents impairment of the counterregulatory response in recurrently hypoglycaemic diabetic rats.
Topics: Adrenergic beta-Antagonists; Animals; Awareness; Carvedilol; Deoxyglucose; Diabetes Mellitus, Experi | 2021 |
Comparison of carvedilol versus metoprolol in patients with acute myocardial infarction: A protocol for systematic review and meta-analysis.
Topics: Arrhythmias, Cardiac; Carvedilol; Death, Sudden, Cardiac; Humans; Meta-Analysis as Topic; Metoprolol | 2021 |
Carvedilol prevents counterregulatory failure and impaired hypoglycaemia awareness in non-diabetic recurrently hypoglycaemic rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Blood Glucose; Body Weight; Carvedilol; Catheteriza | 2019 |
Addition of Carvedilol to Gastric Variceal Obturation Does Not Decrease Recurrence of Gastric Variceal Bleeding in Patients With Cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carvedilol; Endoscopy, Gastrointestinal | 2019 |
Update on pharmacological advances.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Disea | 2004 |
Termination of recurrent ventricular tachycardia by continuous positive airway pressure ventilation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, H | 2009 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos | 2010 |
Intractable recurrent ventricular tachycardia in dilated cardiomyopathy controlled by a vasodilating beta blocker.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Humans; | 1997 |